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Thyroid hormone is crucial for growth and development 
in every stage of life. Without proper tuning of thyroid 
hormone activity, adverse effects on cognitive function, 
bone mineralisation, and energy metabolism are 
common. In case of thyroid hormone deficiency 
(hypothyroidism),  weight gain,  mood impairment,  and  
 
 
dyslipidaemia are prevalent problems [1]. Thyroid 
hormone excess (hyperthyroidism) may lead to atrial 
fibrillation, muscle wasting, weight loss and 
osteoporosis [2, 3]. Even within the normal range 
(euthyroidism), variations in thyroid status have been 
associated with cardiovascular risk and body 
composition [4].  
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The  relationship between  thyroid  status and  longevity has been  investigated extensively. However, data on
thyroid  status  and  survival  in  old  age  is  scarce.  In  this  study  we  investigated  associations  of  different
parameters of thyroid status with mortality in nonagenarians, and whether these associations were different in
nonagenarians  from  long‐lived  families  than  in  nonagenarians  from  the  general  population.  In  total,  805
nonagenarians  from  the  Leiden Longevity Study and 259 nonagenarians  from  the  Leiden 85‐plus Study were
followed  up  to  collect mortality data. At baseline,  levels of  thyrotropin  (TSH),  free  thyroxine  (fT4)  and  free
triiodothyronine  (fT3)  were  measured.  In  nonagenarians  from  long‐lived  families  and  from  the  general
population,  associations  between  thyroid  parameters  and mortality were  similar. We  found  no  interaction
between study population and parameters of thyroid status on mortality (P‐values>0.70). The results from both
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Circulating thyroid hormone levels are regulated by the 
hypothalamus-pituitary-thyroid (HPT) axis [5]. First the 
hypothalamus secretes thyrotropin releasing hormone 
(TRH), inducing release of thyrotropin (TSH) by the 
pituitary. TSH then stimulates the thyroid gland to 
synthesise and secrete thyroid hormones, consisting of 
the prohormone thyroxine (T4) and the active hormone 
triiodothyronine (T3). Most of T4 and T3 is bound to 
binding proteins, resulting in only a small fraction of 
unbound, free T4 (fT4) and unbound, free T3 (fT3) in 
the circulation. Subsequently, through negative feed-
back, the hypothalamus and pituitary gland adjust 
secretion of TRH and TSH to circulating levels of fT4. 
In peripheral tissues, fT4 is converted by tissue specific 
deiodinases to customize local availability of active T3. 
Previously, indications were found of a relationship 
between lower thyroid status and longevity. In the 
Leiden 85-plus Study, a prospective population-based 
study in the city of Leiden in the Netherlands [6], higher 
levels of TSH were associated with lower mortality in 
participants between ages 85 and 90 [7]. Furthermore, 
in the Leiden Longevity Study, a family study of 
siblings with exceptional longevity [8, 9], slightly 
higher levels of circulating TSH and lower levels of fT4 
and fT3 were associated with increased familial 
longevity [10]. The offspring of these old age siblings 
had higher TSH levels than their partners, while they 
had similar levels of fT4 and fT3 [11]. Taken together, 
these studies suggest a different HPT-axis set point as a 
familial trait of long-lived families. However, data on 
associations between thyroid status and survival at 
exceptionally old age are scarce and no data are 
available on whether these associations are similar in 
nonagenarians from long-lived families as compared to 
nonagenarians from the general population.  
 
To address these questions, we assessed and compared 
the associations between parameters of thyroid status 
and mortality in two nonagenarian study populations; 





Characteristics of study populations 
 
Characteristics of the nonagenarian participants of the 
Leiden Longevity Study and the Leiden 85-plus Study 
are presented separately for the 384 men and 680 
women in Table 1. For the Leiden Longevity Study, 
male participants were younger (91.4 years) than the 
female participants (93.6 years, P<0.001). Circulating 
levels of fT3 were significantly higher in men (4.1 
pmol/L) than in women (4.0 pmol/L, P=0.001). The 
women had lower fT3/fT4 ratios (0.25) compared to the 
men (0.26, P<0.001). The other parameters were not 
significantly different. In the Leiden 85-plus Study, 
measurements performed at age 90 years were taken as 
baseline for both men and women. Levels of high-
sensitivity C-reactive protein (hsCRP) were 
significantly different between men and women (men 
3.7 mg/L, women 2.8 mg/L, P=0.02). All other 
measured parameters were similar for men and women. 
  
Thyroid status and mortality in long-lived families 
 
In Table 2 the associations between thyroid status 
parameters and mortality rate in the participants of the 
Leiden Longevity Study are presented. For levels of 
TSH, no association with mortality rate was found. For 
levels of fT4, a more than 20 percent increased 
mortality rate was observed in the highest tertile 
compared to the lowest, however statistical significance 
was lost after correction for hsCRP (model 1 hazard 
ratio (HR) 1.22 (95% CI 1.01-1.48) P=0.04, model 2 
HR 1.21 (95% CI 0.99-1.45) P=0.06). Higher levels of 
fT3 were associated with lower mortality in both 
models (model 1 HR 0.70 (95% CI 0.58-0.85) 
P=2.33x10-4, model 2 HR 0.73 (95% CI 0.60-0.88) 
P=1.33x10-3). The fT4xTSH product and the fT4/TSH 
ratio were not associated with mortality in either model. 
The highest tertile of the fT3/fT4 ratio had more than 30 
percent reduction in mortality rate compared to the 
lowest tertile (model 1 HR 0.65 (95% CI 0.54-0.79) 
P=1.65x10-5, model 2 HR 0.68 (95% CI 0.56-0.83) 
P=1.13x10-4). The results were similar for men and 
women in the stratified analyses (data not shown).    
 
Thyroid status and mortality in the general 
population  
 
The association between thyroid status parameters and 
mortality rate in participants of the Leiden 85-plus 
Study are presented in Table 3. Similar to the results in 
the participants of the Leiden Longevity Study, levels of 
TSH were not associated with mortality. Higher levels 
of fT4 were associated with an increased mortality rate 
in both models, though statistical significance was not 
reached (model 1 HR 1.36 (95% CI 1.00-1.84) P=0.05, 
model 2 HR 1.27 (95% CI 0.93-1.73) P=0.14). The 
highest tertile of fT3 had a significantly lower mortality 
rate than the lowest tertile (model 1 HR 0.66 (95% CI 
0.49-0.90) P=0.01, model 2 HR 0.72 (95% CI 0.53-
0.98) P=0.04) The fT4xTSH product and the fT4/TSH 
ratio were not associated with mortality rate. The 
fT3/fT4 ratio was associated with a more than 40 
percent decrease in mortality rate in both models in the 
highest compared to the lowest tertile (model 1 HR 0.55 
(95% CI 0.40-0.75) P=1.44x10-4, model 2 HR 0.59 
(95% CI 0.43-0.81) P=9.66x10-4).  The results were 
similar for men and women in the stratified analyses 
(data not shown).   

















































Thyroid status and mortality independent of study 
population 
 
The results of the stratified analyses on thyroid status 
and mortality were similar for both nonagenarians of 
long-lived families and of the general population. When 
interaction was tested between study population and 

















































interaction was found (all P-values>0.7, Supplementary 
Table 1). 
 
Generalized results for nonagenarians 
 
Since the associations between thyroid status and 
mortality were similar in both nonagenarian popu-
lations, the results could be combined to provide a 
Table 1. Characteristics of the participants of the Leiden Longevity Study and the Leiden 85‐
plus Study. 
 Men Women P-value 
Leiden Longevity Study    
Number of participants 312 493  
Age (years) 91.4 (90.1-93.7) 93.6 (92.2-95.3) <0.01 
Deceased (n (%)) 287 (92.0) 462 (93.7) 0.88 
TSH (mU/L) 1.6 (1.0-2.4) 1.5 (1.0-2.4) 0.16 
fT4 (pmol/L) 15.8 (2.0) 16.1 (2.4) 0.08 
fT3 (pmol/L) 4.1 (0.6) 4.0 (0.5) <0.01 
fT4xTSH (pmolxmU) 25.3 (16.3-36.2) 24.1 (15.6-37.5) 0.26 
fT4/TSH (pmol/mU) 9.9 (6.2-14.9) 10.8 (6.3-17.2) 0.10 
fT3/fT4 0.26 (0.05) 0.25 (0.04) <0.01 
hsCRP (mg/L)a  3.0 (1.4-6.6) 2.6 (1.2-5.2) 0.13 
    
Leiden 85-plus Study    
Number of participants 72 187  
Age (years) 90 90  
Deceased (n (%)) 71 (98.6) 183 (97.9) 0.16 
TSH (mU/L) 1.9 (1.1-3.0) 1.7 (1.0-2.9) 0.46 
fT4 (pmol/L) 16.2 (2.5) 16.3 (2.2) 0.80 
fT3 (pmol/L) 4.0 (0.5) 4.1 (0.6) 0.27 
fT4xTSH (pmolxmU) 30.5 (19.5-47.0) 26.9 (18.1-44.2) 0.41 
fT4/TSH (pmol/mU) 8.4 (5.0-15.9) 9.2 (5.2-16.3) 0.49 
fT3/fT4 0.25 (0.05) 0.26 (0.04) 0.94 
hsCRP (mg/L)  3.7 (2.0-8.3) 2.8 (1.2-5.8) 0.02 




www.aging‐us.com  2226  AGING 
generalizable association for nonagenarians. For this 
purpose, the results for the Leiden Longevity Study and 
the Leiden 85-plus Study populations were combined, 
through a fixed-effects inverse-variance weighted 
analysis on the associations of thyroid parameters and 
mortality rate with adjustments as described in model 2 
(Supplementary Table 2). The HRs of the highest 

















































weighted averages of these HRs are displayed in Figure 
1. Higher levels of TSH were not associated with 
mortality rate in either study or in the pooled analysis 
(HR 0.91, 95% CI 0.78-1.07, P=0.25). Higher levels of 
fT4 were associated with higher mortality rate in both 
studies, leading to an increase of 22 percent in mortality 
rate in the highest compared to the lowest fT4 tertile in 


















































   Leiden Longevity Study participants    
  

















TSH       
Lowest tertile 0.9 (0.1-1.2) 0.7 (0.1-1.1) 1.00 (reference)  1.00 (reference)  
Middle tertile 1.6 (1.2-2.1) 1.5 (1.1-2.0) 0.92 (0.78-1.08) 0.30 0.91 (0.77-1.07) 0.24 
Highest tertile 3.0 (2.1-11.7) 3.0 (2.0-17.3) 0.95 (0.79-1.14) 0.49 0.93 (0.77-1.12) 0.44 
       
fT4       
Lowest tertile 13.8 (10.2-14.7) 13.7 (10.1-15.0) 1.00 (reference)  1.00 (reference)  
Middle tertile 15.6 (14.8-16.6) 16.0 (15.1-16.9) 0.91 (0.75-1.09) 0.30 0.92 (0.76-1.10) 0.36 
Highest tertile 17.7 (16.7-22.1) 18.3 (17.0-23.5) 1.22 (1.01-1.48) 0.04 1.21 (0.99-1.45) 0.06 
       
fT3       
Lowest tertile 3.6 (2.6-3.8) 3.5 (2.6-3.7) 1.00 (reference)  1.00 (reference)  
Middle tertile 4.1 (3.9-4.3) 3.9 (3.8-4.1) 0.77 (0.64-0.93) 0.01 0.78 (0.65-0.94) 0.01 
Highest tertile 4.6 (4.4-5.8) 4.5 (4.2-5.8) 0.70 (0.58-0.85) <0.01 0.73 (0.60-0.88) <0.01 
       
fT4xTSH       
Lowest tertile 14.0 (2.0-19.5) 12.3 (1.6-18.2) 1.00 (reference)  1.00 (reference)  
Middle tertile 25.3 (19.5-32.1) 24.1 (18.2-30.9) 1.00 (0.84-1.18) 0.96 0.99 (0.84-1.18) 0.93 
Highest tertile 45.6 (32.2-212.9) 46.9 (31.1-257.5) 1.01 (0.83-1.22) 0.92 1.01 (0.83-1.22) 0.94 
       
fT4/TSH       
Lowest tertile 5.2 (1.2-7.5) 4.8 (0.6-7.8) 1.00 (reference)  1.00 (reference)  
Middle tertile 9.9 (7.5-13.0) 10.8 (7.8-14.3) 0.92 (0.77-1.10) 0.35 0.92 (0.77-1.10) 0.34 
Highest tertile 18.6 (13.1-136.7) 22.5 (14.3-235.0) 1.07 (0.90-1.29) 0.44 1.08 (0.91-1.29) 0.38 
       
fT3/fT4       
Lowest tertile 0.22 (0.14-0.24) 0.21 (0.12-0.23) 1.00 (reference)  1.00 (reference)  
Middle tertile 0.26 (0.24-0.28) 0.25 (0.23-0.27) 0.73 (0.61-0.88) <0.01 0.75 (0.63-0.90) <0.01 






















































Inversely, higher levels of fT3 were associated with 
lower mortality rates in both studies, resulting in a 
decrease in mortality rate of more than 25 percent in the 
highest compared to the lowest tertile (HR 0.73, 95% CI 
0.62-0.86, P=1.31x10-4). The fT4xTSH product and the 
fT4/TSH ratio were not associated with mortality rate. 
Lastly, the fT3/fT4 ratio was associated with a lower 

















































lowest in both studies, resulting in a 35 percent lower 
mortality rate in the pooled analysis (HR 0.65, 95% CI 
0.55-0.77, P=5.64x10-7). 
 
Various sensitivity analyses 
  
Sensitivity analyses performed on participants with 
normal levels of hsCRP (hsCRP<10 mg/L), participants 
Table 3. Parameters of thyroid status and mortality rate in the Leiden 85‐plus Study.
   Leiden 85-plus Study participants    















TSH       
Lowest tertile 0.9  (0.1-1.3) 0.8 (0.1-1.2) 1.00 (reference)  1.00 (reference)  
Middle tertile 1.9 (1.4-2.7) 1.7 (1.3-2.4) 0.87 (0.64-1.18) 0.38 0.91 (0.67-1.23) 0.53 
Highest tertile 3.9 (2.7-7.5) 3.5 (2.4-14.6) 0.86 (0.64-1.17) 0.35 0.87 (0.64-1.17) 0.35 
       
fT4       
Lowest tertile 13.8 (11.5-14.6) 14.3 (11.2-15.3) 1.00 (reference)  1.00 (reference)  
Middle tertile 16.2 (14.7-17.4) 16.2 (15.4-17.1) 1.37 (1.01-1.86) 0.05 1.35 (0.99-1.83) 0.06 
Highest tertile 18.9 (17.5-22.2) 18.3 (17.2-23.2) 1.36 (1.00-1.84) 0.05 1.27 (0.93-1.73) 0.14 
       
fT3       
Lowest tertile 3.6 (2.7-3.8) 3.5 (2.8-3.8) 1.00 (reference)  1.00 (reference)  
Middle tertile 4.0 (3.9-4.1) 4.0 (3.9-4.3) 0.77 (0.57-1.06) 0.11 0.82 (0.60-1.12) 0.21 
Highest tertile 4.4 (4.2-5.7) 4.7 (4.4-5.9) 0.66 (0.49-0.90) 0.01 0.72 (0.53-0.98) 0.04 
       
fT4xTSH       
Lowest tertile 15.0 (1.8-23.1) 13.7 (2.0-20.1) 1.00 (reference)  1.00 (reference)  
Middle tertile 30.5 (23.2-42.7) 26.9 (20.5-39.0) 1.21 (0.89-1.64) 0.23 1.24 (0.91-1.69) 0.17 
Highest tertile 57.4 (43.8-108.2) 57.5 (39.0-210.5) 0.98 (0.72-1.33) 0.89 0.98 (0.72-1.33) 0.88 
       
fT4/TSH       
Lowest tertile 3.5 (1.8-5.9) 4.6 (0.8-6.4) 1.00 (reference)  1.00 (reference)  
Middle tertile 8.4 (6.1-12.0) 9.2 (6.4-13.7) 0.97 (0.72-1.32) 0.86 1.01 (0.74-1.36) 0.96 
Highest tertile 17.3 (12.6-181.0) 21.1 (13.7-165.8) 1.12 (0.83-1.52) 0.46 1.12 (0.83-1.52) 0.46 
       
fT3/fT4       
Lowest tertile 0.21 (0.13-0.23) 0.22 (0.14-0.24) 1.00 (reference)  1.00 (reference)  
Middle tertile 0.25 (0.23-0.27) 0.26 (0.24-0.27) 0.73 (0.54-0.98) 0.04 0.76 (0.56-1.03) 0.07 
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with mortality within the first two years or past the first 
year of follow up did not materially change the results 
(data not shown). The results were similar in 
participants with TSH levels within the normal range as 




This study assessed the association between parameters 
of thyroid status and mortality rate in nonagenarians 
from long-lived families and the general population. In 
both populations, a higher fT3/fT4 ratio was associated 
with decreased mortality rate. Although the observed 
associations for the levels of fT3 and fT4 within the 
reference range were not identical for the two 
populations, these showed a similar pattern. When the 
results of both populations were combined, higher 
levels of fT3 within the reference were associated with 



































within the reference range were detrimental in old age. 
Risk of mortality was neither associated with levels of 
TSH nor with the fT4xTSH product or the fT4/TSH 
ratio. All observed relationships between thyroid status 
and risk of mortality were consistent in male and female 
participants and in participants with TSH levels within 
the normal range. 
 
The fT3/fT4 ratio can be viewed as an estimate of 
conversion of fT4 into fT3 [12]. Conversion of fT4 
takes place by deiodinases in peripheral tissues such as 
the liver, the kidneys and skeletal muscle as well as 
inside the thyroid gland [13]. Our result of a lower 
mortality rate in the participants with the highest 
fT3/fT4 ratios in nonagenarians is consistent with the 
previous finding of Gussekloo et al. [7] in participants 
of the Leiden 85-plus Study aged 85 to 89 years old. 
One of the possible explanations for this association is 
that individuals with a lower fT3/fT4 ratio are ill. In 






































95%  confidence  intervals  for mortality  of  the  highest  sex‐specific  tertiles  compared  to  the  lowest  sex‐specific
tertiles  are  shown  for  the  Leiden  Longevity  Study  participants,  the  Leiden  85‐plus  Study  participants  and  the
pooled Hazard ratios.   LLS = participants of the Leiden Longevity Study, 85‐plus = participants of the Leiden 85‐
plus Study, LLS and 85‐plus = combined estimates of the Leiden Longevity Study and the Leiden 85‐plus Study. 
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T4 to T3 is inhibited by downregulation of type 1 
deiodinase (D1) known as euthyroid sick syndrome 
[14]. However, when we adjusted for levels of C-
reactive protein as a marker of inflammation, the 
observed association was not attenuated.  
 
The increased risk of mortality with higher levels of fT4 
could be a reflection of lower turnover. This could be 
due to decreased conversion of fT4 by deiodinases, 
congruent to the observation with the fT3/fT4 ratio. 
Alternatively, higher circulating levels of fT4 might 
reflect a slower rate of detoxification of thyroid 
hormones (and possibly other compounds) by the liver 
and kidney which would be unfavourable for survival. 
These associations are in line with previous 
observations [7, 15-18]. 
 
The association between higher circulating levels of fT3 
and lower mortality is in line with previous research. A 
higher BMI was found to be causally related to higher 
circulating levels of fT3 [19], and higher BMI has also 
been positively associated with old age survival [20]. 
The lower risk of mortality with higher levels of fT3 we 
found was reported by others only in crude analyses 
when illness was not taken into account [18, 21, 22]. 
Yet, adjustment for levels of hsCRP did not materially 
influence the results. 
 
Circulating levels of TSH appear to play no major role 
in risk of mortality in our nonagenarian populations, 
which matches the inconclusive results in literature [7, 
15, 17, 22-27]. In previously described analyses, 
decreased mortality with increasing levels of TSH was 
observed in the prolonged follow-up of the 85-plus 
Study [5]. However, in participants with TSH levels 
within the normal range the decrease in mortality was 
not significant, which is in line with our study in which 
the participants with extreme values of TSH were 
excluded. 
 
No relationship was found between mortality risk and 
the fT4xTSH product, which is a reflection of resistance 
to thyroid hormones due to thyroid hormone receptor 
defects [11, 28]. In mice, the influence on mortality 
depends on the affected receptor type. Defects in the β-
receptor cause only marginal increase in mortality 
whereas α-receptor defects are associated with severely 
shortened lifespan [29]. Data on the effects of fT4xTSH 
in humans are scarce and no data is available for milder 
variations within populations. 
 
The fT4/TSH ratio was also not associated with 
mortality rate in this study. This ratio combines the 
levels of fT4 and TSH, resulting in a composite measure 
which could reflect the responsiveness of the thyroid 
gland to TSH, a trait previously associated with familial 
longevity [10, 11, 30-32]. Possibly the influence of this 
trait is only found earlier in life, because selection for 
individuals with this trait has taken place by age 90 
years. 
 
The consistency of our results in both nonagenarian 
populations advocates a universal mechanism of 
survival in old age via relatively lower levels of fT4 and 
higher fT3. Even though nonagenarians from long-lived 
families exhibit demonstrably lower mortality rate than 
nonagenarians from the general population [9], a higher 
fT3/fT4 ratio appears to be a common trait associated 
with longevity. 
  
One of the strengths of this study is that we used data 
from a relatively large population of a rarely 
investigated age category of nonagenarians. The study 
participants originated from two different study 
populations with different study designs and inclusion 
criteria. This has led to a high heterogeneity in study 
population, which allows extrapolation of these results 
to nonagenarians in the general population. Another 
quality of this study is the use of multiple parameters of 
thyroid status, which could offer more insight into the 
interplay of these parameters. These continuous values 
of proportions are preferable over clinical cut off points 
for clinical and subclinical thyroid dysfunction for two 
reasons. Firstly, these continuous variables allow for a 
more mechanistic approach. Secondly, the diagnostic 
criteria for thyroid dysfunction and normal ranges of 
TSH and fT4 differ over time, per country and per 
laboratory [33, 34]. Limitations of this study are the 
lack of information on thyroid disease and use of 
medication affecting the thyroid, as well as general 
information on chronic and acute illness. 
     
In conclusion, we have found lower mortality rate 
associated with a higher fT3/fT4 ratio, lower fT4 levels, 
and higher fT3 levels in nonagenarians from long-lived 
families and from the general population. Based on the 
results of the present study, associations of thyroid 
status with old age mortality were not dependent on 
familial longevity status. To identify the causal 
mechanisms underlying the observed associations 
between thyroid status and mortality, future research 
should focus on biological mechanisms via which 




Leiden Longevity Study 
 
As described previously in more detail, the aim of the 
Leiden Longevity Study is to identify genetic and 
phenotypical factors contributing to familial longevity 
[8, 9]. Families were included if at least two proband 
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siblings had lived to exceptionally old age, being 89 
years or older for men and 91 years or older for women. 
No exclusion criteria based on health or demographics 
were applied. The Medical Ethical Committee of the 
Leiden University Medical Centre approved the study 
and written informed consent was obtained from all 
study participants. Between July 2002 and May 2006, 
421 Dutch Caucasian families were recruited, 
comprising 944 nonagenarian participants.  
 
Of these 944 nonagenarians data on TSH, fT4 and fT3 
were available for 859 participants. Three participants 
were excluded from the analyses because serum TSH 
levels were outside the detection range (two participants 
with TSH <0.005 mU/L and one participant with TSH 
>100mU/L). Four participants were excluded because 
their fT3 level was below the reference range (<2.5 
pmol/L), as a possible sign of euthyroid sick syndrome. 
Lastly, 16 participants were excluded because their fT4 
levels were outside the reference range (six participants 
with <10.0 pmol/L and ten participants with >24.0 
pmol/L), because of presumed thyroid disease or 
medication use affecting the thyroid function. 
Subsequently, participants with (log transformed) TSH 
or fT4 or one of the composite measurements ((log 
transformed) fT4xTSH product, (log transformed) 
fT4/TSH ratio, or fT3/fT4 ratio) that deviated more than 
three standard deviations from the population mean 
were excluded. Of the included 805 participants, 749 
had passed away on the 1st of February 2014. The 
median follow up time was 3.49 years, with 
interquartile range of 1.53 to 4.97 years.   
 
Leiden 85-plus study 
 
The Leiden 85-plus Study is a prospective, population-
based study aimed at investigating determinants of 
successful aging [6]. Inclusion criteria were being 85 
years old and living in Leiden, the Netherlands, between 
September 1997 and September 1999. No exclusion 
criteria based on health were applied. Out of 705 
eligible individuals 599 participants were enrolled, 
since 92 people had refused and 14 were deceased 
before the assessment visit. Over a follow-up period of 
five years, participants were assessed annually until 
death or refusal. The study was approved by the 
Medical Ethical Committee of the Leiden University 
Medical Centre and all participants provided oral 
informed consent. 
 
To investigate a similar age group as the Leiden 
Longevity Study, the current study used data of the 
participants of the Leiden 85-plus Study at the age of 
ninety years. Out of the 599 participants enrolled at 85 
years, 52 had refused to continue participation and 270 
were deceased before the assessment visit following 
their 90th birthday. From the total of 277 nonagenarian 
participants who were eligible, three participants did not 
provide a blood sample and three had missing data on 
TSH level. One participant was excluded because the 
serum fT3 level was below the reference range (<2.5 
pmol/L) and two participants were excluded for having 
serum levels of fT4 below the reference range (10.0 
pmol/L). Of the remaining 268 participants, those with 
thyroid status parameters (where appropriate log 
transformed) that deviated more than three standard 
deviations from the population mean were excluded. In 
total, 259 participants were included, of which 254 had 
passed away on the 1st of February 2014. The median 
follow up time was 3.84 years, with interquartile range 




For both the Leiden Longevity Study and the Leiden 
85-plus Study, non-fasted blood samples were collected 
from all participants between 09:30 hours and 17:00 
hours at the assessment visit. Measurements of TSH, 
fT4 and fT3 were performed using the Modular E170 
from Roche, Almere, the Netherlands. The reference 
ranges at our laboratory are 0.3-4.8 mU/L for TSH 
(detection range 0.005-100 mU/L), 10.0-24.0 pmol/L 
for fT4 (detection range 1.3-100 pmol/L) and 2.5-5.5 
pmol/L for fT3 (detection range 0.400-50.0 pmol/L). 
High-sensitivity C-reactive protein (hsCRP) (detection 
range 0.3-350 mg/L) was measured using Cobas Integra 
800 from Roche, Almere, the Netherlands. All coef-
ficients of variation were below 5%. The measurements 
were performed in a single batch at the Department of 
Clinical Chemistry of the Leiden University Medical 
Centre. 
 
Composite measurements of thyroid status 
 
To assess the thyroid status in more detail, three 
composite measurements were computed. The product 
of fT4 and TSH (fT4xTSH) was calculated, to allow for 
assessment of the sensitivity of the pituitary thyrotrophs 
to feedback regulation by thyroid hormones as des-
cribed previously [11, 28]. Furthermore, the ratio of fT4 
and TSH (fT4/TSH) was calculated, as a measure of 
responsiveness of the thyroid gland to TSH as proposed 
by Jansen et al. [11]. The ratio of fT3 and fT4 (fT3/fT4) 





Because of the study design of the Leiden Longevity 
Study in which the men are younger than the women, 
all analyses were performed on men and women 
separately. Means and standard deviations, and where 
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appropriate medians and interquartile ranges, were 
computed for parameters of thyroid status and age and 
hsCRP for male and female participants of both the 
Leiden Longevity Study and the Leiden 85-plus Study. 
Differences between men and women were tested using 
the T-test, Chi-Square test, or Mann-Whitney U test. 
Secondly, the participants of both studies were divided 
over sex-specific tertiles based on TSH, fT4, fT3, the 
fT4xTSH product, the fT4/TSH ratio, or the fT3/fT4 
ratio. Survival analyses were performed using Cox 
regression on combined tertiles of men and women in 
both studies and in men and women separately using 
two statistical models. In model 1 for the Leiden 
Longevity Study, the analyses were adjusted for 
differences in age at entry by left truncated analysis and 
adding age at entry as an independent variable. 
Furthermore, robust standard errors were used to correct 
for siblingship by clustering on family number of the 
Leiden Longevity Study participants. For the Leiden 85-
plus Study, model 1 was a crude analysis. In model 2, 
hsCRP was added as an independent variable, to adjust 
for inflammation, for both the Leiden Longevity Study 
and the Leiden 85-plus Study. The outcomes were 
presented as hazard ratios (HRs) for tertiles with the 
lowest tertile as a reference. To formally test whether 
the associations between parameters of thyroid status 
and mortality were similar for nonagenarians of long-
lived families and the general population, interaction 
between study population (long-lived families or the 
general population) and parameters of thyroid status on 
mortality was tested by adding an interaction term and 
population of origin as covariates to the model 2 
analysis excluding familial clustering. To assess a 
generalizable result for nonagenarian populations, the 
results were analyzed using a fixed-effects inverse-
variance weighted analysis based on the coefficient for 
the highest tertile compared to the lowest tertile and its 
Standard Error in Cox regression. The output was 
transformed to HR. As sensitivity analyses we perform-
ed the same analyses in participants with hsCRP <10 
mg/L, in participants who had passed away in the first 
two years of follow up, in participants who had survived 
the first year of follow up, and in participants with TSH 
levels within the normal range. In the analyses values of 
P<0.05 were considered significant. For data analyses 
Statistical Package for the Social Sciences (SPSS) 
version 23, the Stata Data analysis and Statistical 
Software for Windows version 12.0 SE and R version 
3.2.4 for Windows were used. The graph was created 
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Data  are  presented  as  P‐value  for  interaction  term  for 




Parameter of thyroid status Hazard ratio (95% 
CI) 
P-value 
TSH 0.91 (0.78-1.07) 0.25 
fT4 1.22 (1.04-1.43) 0.02 
fT3 0.73 (0.62-0.86) 1.31x10-4 
fT4xTSH 1.00 (0.85-1.17) 0.99 
fT4/TSH 1.09 (0.94-1.27) 0.26 
fT3/fT4 0.65 (0.55-0.77) 5.64x10-7 
Data  are  presented  as  Hazard  ratios  for  weighted  averages  of 
mortality rates of the highest compared to lowest sex‐specific tertiles 
in the Leiden Longevity Study and the Leiden 85‐plus Study. 
